Global Cholesteatoma Treatment Market - 2022-2029

Global Cholesteatoma Treatment Market - 2022-2029

Market Overview

The global cholesteatoma treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

C2holesteatoma is a skin-lined cyst that starts at the eardrum's edge and spreads to the middle ear and mastoid bone (arrow). Cholesteatoma can be a congenital disability (congenital). It's more likely to happen due to a long-term ear infection.

Market Dynamics

The factors influencing the global cholesteatoma treatment market are the increasing demand for cholesteatoma treatment and the growing prevalence of cholesteatoma.

The increasing demand for cholesteatoma treatment is expected to drive the market growth

Cholesteatoma is a degenerative ear disease that can affect people of all ages. It has been discovered that children and young adults are more affected. It erodes the middle ear, mastoid, and ossicles' surrounding bone. It causes deafness ranging from partial to total and pain, tinnitus, vertigo, and facial paralysis. It can cause meningitis, a brain abscess, and even death. A cholesteatoma can only be treated by having it surgically removed. It must be removed to avoid the complications that can arise if the cyst grows larger. Cholesteatomas do not disappear on their own. They typically continue to grow and cause more issues. In mastoidectomy, the disease will be removed by opening the bone. To create an open cavity, one may need to remove all of the bony walls within the ear. An open cavity, canal wall down, or radical mastoidectomy describes this procedure. A canal wall up or closed cavity mastoidectomy can be performed when the bony partitions are preserved. Moreover, the increasing number of mastoidectomy surgery is expected to drive the treatment demand. For instance, throughout the 10-year study, 158 mastoidectomies were performed for various reasons. This translates to a 9.9 per 100,000 annual incidence rate. This is comparable to the reported incidence of mastoidectomy in the United States, ranging from 7.3 to 27.4 per 100,000.

The limitations associated with cholesteatoma treatment are expected to hamper the market growth

The recurrence of cholesteatoma in the attic or retrotympanic space due to incomplete removal of the squamous epithelium is one of the drawbacks of the so-called closed techniques. The classical closed technique has a recurrence rate of up to 35%. In cases of cholesteatoma, the lateral attic wall has already been destroyed, and this defect persists after posterior tympanotomy. Aside from the high recurrence rate, another risk is the development of an epitympanic retraction pocket due to the original lateral attic wall defect, which can lead to a new cholesteatoma over time.

Further hearing loss, tinnitus, imbalance or vertigo, taste dysfunction, and facial weakness are the main risks of surgery. One to two weeks off work are required in the short term, and one to two months of postoperative dressings. Six to twelve-monthly follow-ups are required after surgery to check for recurrence. Some patients will need to be monitored for the rest of their lives. When the inflammation subsides, some techniques require a second look procedure to ensure that the cholesteatoma has not recurred and reconstruct the hearing by replacing the eroded middle ear bones.

COVID-19 Impact Analysis

COVID-19 is a highly contagious viral infection with a high risk of transmission during otolaryngology exams and surgery. Cholesteatoma is known for its risk of complications, so surgery during the pandemic needs to be carefully planned. The majority of otological surgeries can be classified as elective and postponed at this time (e.g., stapedotomy, tympanoplasty); however, some are emergencies (e.g., complicated acute otitis media, complicated cholesteatoma with cerebral or Bezold's abscess, meningitis, sinus thrombosis) and require immediate intervention (e.g., complicated acute otitis media, complicated cholesteatoma.

The upper respiratory mucosa of a COVID-19-infected patient has a high viral load, which increases the risk of transmission during otolaryngology examinations and surgery. Most cholesteatoma surgeries are elective and can be postponed at this time; however, some are emergencies (complicated cholesteatoma with cerebral or Bezold's abscess, meningitis, sinus thrombosis, facial palsy) and must be treated right away. In recent times, more than ever, any surgical management decision must be based on a risk-benefit analysis tailored to the individual patient. Surgery and even follow-up visits may be postponed for some patients. Hence, due to the delay in surgical procedures and treatment, the market growth is expected to be hampered.

Segment Analysis

Based on treatment type, the surgical segment is expected to dominate the market growth

Surgical treatment is the only option once a cholesteatoma is discovered, even if it is rarely necessary. A mastoidectomy is usually performed to remove the disease from the bone, and a tympanoplasty is performed to repair the eardrum. The disease's stage determines the type of operation required at the time of surgery. Open mastoidectomy with reconstruction in a single surgical procedure is a highly successful (93%) technique for treating cholesteatoma, with recurrence rates three to four times lower than those reported in the literature and hearing preservation. This technique keeps the cavity from filling up with scabs, fungus, and bacterial infections repeatedly, as well as saving the patient money by avoiding a second surgery and saving the institution money. However, it necessitates a highly personalized approach that considers the patient's anatomical, clinical, and social factors in determining the most effective surgical treatment.

In 2018, the female population had a 1.27-fold higher rate of COM operations than the male population. In 2018, however, the male population had a 1.2-fold higher rate of cholesteatoma surgery than the female population. According to the 2018 data, COM operations were most commonly performed in patients in their 50s. In patients aged 51–80, the number of COM operations increased rapidly.

Geographical Analysis

North America region is expected to hold the largest market share in the global cholesteatoma treatment market

The growing prevalence of cholesteatoma and better healthcare facilities in this region is expected to dominate the market growth.

Cholesteatoma is a rare condition in which benign skin growth forms just behind the eardrum in the middle ear. In the United States, only nine out of every 100,000 adults are diagnosed with these skin growths each year. While cholesteatoma is not cancerous, it will continue to grow and cause serious problems if not removed. In the United States, most cholesteatoma surgical procedures are now done through an incision behind the ear combined with an incision in the external auditory canal. Still, the procedure can also be done through an extended incision beginning in the ear canal.

Competitive Landscape

With mergers, acquisitions, and product launches, the global cholesteatoma treatment market is moderately competitive. Some of the key players in the market are WraSer LLC, Novartis AG, Otonomy, Inc, Bayer AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Dr. Reddy’s Laboratories Ltd, Mylan N.V., Aurobindo Pharma USA

Novartis AG

Overview: Novartis International AG, based in Basel, Switzerland, is a multinational pharmaceutical corporation. The company was founded in 1996. Innovative Medicines, Sandoz (generics), and Alcon are the three operating divisions that makeup Novartis (eyecare). Novartis spun off Alcon into a separate company in April 2019.

Product Portfolio: Ciprodex combines ciprofloxacin, a fluoroquinolone antibacterial, and dexamethasone. This corticosteroid is used to treat infections caused by susceptible isolates of the following microorganisms in the following conditions acute otitis media (AOM) caused by staphylococcus aureus, streptococcus pneumonia, haemophilus influenza, moraxella catarrhalis, and pseudomonas aeruginosa in paediatric patients (age 6 months and older) with tympanostomy tubes. Acute otitis externa (AOE) is caused by staphylococcus aureus and pseudomonas aeruginosa in pediatric (age 6 months and older), adult, and elderly patients.

Why Purchase the Report?

Visualize the composition of the global cholesteatoma treatment market segmentation by treatment and end user highlighting the key commercial assets and players.

Identify commercial opportunities in global cholesteatoma treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global cholesteatoma treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cholesteatoma treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers